Frontiers in public health

Measures used to track recovery in long COVID clinical trials

Updated

Abstract

Approximately 10% of people experience after a SARS-CoV-2 infection.

  • Long COVID is a multisystem disease with significant overlap with myalgic encephalomyelitis.
  • Current clinical trials for long COVID and myalgic encephalomyelitis utilize varied outcome measures.
  • A total of 397 outcome measures were identified across 37 myalgic encephalomyelitis trials and 68 long COVID trials.
  • The relevance of these outcome measures for patients was critically assessed.
  • There is an urgent need for high-quality clinical treatment trials to address long COVID.

Simplified

Key numbers

1 trillion US dollars
Economic Cost of
Estimated yearly cost of to the global economy.
50%
Patients Unable to Return to Work
Percentage of patients unable to fulfill work or caregiver roles.
18%
Trials Assessing
Percentage of trials that assess .

Full Text

What this is

  • (LC) affects approximately 10% of individuals post-SARS-CoV-2 infection and presents significant health challenges.
  • This review assesses outcome measures used in clinical trials for LC and myalgic encephalomyelitis (ME), identifying current practices and gaps.
  • The authors provide recommendations for improving the design of future clinical trials to better reflect patient experiences and symptomatology.

Essence

  • Clinical trials for often use outdated and inappropriate outcome measures. This review identifies key issues with current practices and suggests improvements to better capture patient-relevant outcomes.

Key takeaways

  • Over 50% of patients with are unable to return to work, highlighting the severe impact of the condition on daily life.
  • Only 18% of trials assess (), a critical symptom that significantly affects patient quality of life.
  • Many patient-reported outcome measures (PROMs) used in trials are outdated and do not accurately reflect the experiences of patients with or ME.

Caveats

  • This review does not include non-biomedical interventions, which may also provide valuable insights into treatment.
  • The findings are based on existing trials and may not fully represent the evolving understanding of and its outcomes.

Definitions

  • Long COVID: A multisystem disease that develops in approximately 10% of individuals after SARS-CoV-2 infection, leading to persistent symptoms.
  • Post-exertional malaise (PEM): A worsening of symptoms after physical or mental exertion that would not have caused problems before the illness.

Simplified

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free